S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
Log in
NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

$46.42
+0.06 (+0.13 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$45.32
Now: $46.42▼
$47.75
50-Day Range
$36.42
MA: $41.07▼
$44.87
52-Week Range
$30.02
Now: $46.42▼
$58.72
Volume2.00 million shs
Average Volume1.45 million shs
Market Capitalization$7.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.43
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Read More
ACADIA Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
Previous Symbol
CUSIPN/A
CIK1070494
Webwww.acadia-pharm.com
Phone858-558-2871
Employees570

Debt

Debt-to-Equity RatioN/A
Current Ratio8.51
Quick Ratio8.44

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$339.08 million
Price / Sales21.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.54 per share
Price / Book10.22

Profitability

EPS (Most Recent Fiscal Year)($1.60)
Net Income$-235,260,000.00
Net Margins-57.28%
Return on Equity-33.49%
Return on Assets-29.48%

Miscellaneous

Outstanding Shares157,681,000
Market Cap$7.32 billion
Next Earnings Date11/4/2020 (Confirmed)
OptionableOptionable
$46.42
+0.06 (+0.13 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

How has ACADIA Pharmaceuticals' stock price been impacted by Coronavirus?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have increased by 25.9% and is now trading at $46.42.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of ACADIA Pharmaceuticals?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ACADIA Pharmaceuticals.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ACADIA Pharmaceuticals.

How can I listen to ACADIA Pharmaceuticals' earnings call?

ACADIA Pharmaceuticals will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.17. The biopharmaceutical company earned $110.10 million during the quarter, compared to analysts' expectations of $105.65 million. ACADIA Pharmaceuticals had a negative return on equity of 33.49% and a negative net margin of 57.28%.
View ACADIA Pharmaceuticals' earnings history.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $437.26 million.

What price target have analysts set for ACAD?

16 equities research analysts have issued 1-year price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $42.00 to $72.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $59.94 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include Beigene (BGNE), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), Astellas Pharma (ALPMY), Shiseido (SSDOY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX) and BioMarin Pharmaceutical (BMRN).
View all competitors.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 59, Pay $1.36M)
  • Dr. Srdjan R. Stankovic, Pres (Age 63, Pay $1.23M)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 40, Pay $689.09k)
  • Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 56, Pay $700.8k)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 58, Pay $810.41k)
  • Mr. James K. Kihara, VP, Corp. Controller & Principal Accounting Officer (Age 40)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
  • Dr. Eliseo Oreste Salinas, Sr. VP, Chief Scientific Officer & Head of External Innovation (Age 64)
  • Mr. Mark C. Johnson, VP of Investor Relations
  • Mr. Ryan E. Brown, Chief Compliance Officer & VP

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.20%), Peregrine Capital Management LLC (0.12%), Factory Mutual Insurance Co. (0.10%), Wealthstreet Investment Advisors LLC (0.09%), First Midwest Bank Trust Division (0.03%) and Boenning & Scattergood Inc. (0.02%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Nisa Investment Advisors LLC, Exane Derivatives, and Exane Derivatives. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Candriam Luxembourg S.C.A., First Midwest Bank Trust Division, DNB Asset Management AS, Riggs Asset Managment Co. Inc., Round Table Services LLC, Envestnet Asset Management Inc., and Pacer Advisors Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $46.42.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $7.32 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 570 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.